OncoDynamiX reduces lead time with significant cost saving at the discovery stage by selection of appropriate cell lines based on signalling pathways associated with the drug target for LI-LO programs, and also identifies appropriate biomarkers for PK/PD and enables identification of patients for clinical trials to optimise drug response.